DE69826496D1 - RECOMBINANTES IgA - Google Patents

RECOMBINANTES IgA

Info

Publication number
DE69826496D1
DE69826496D1 DE69826496T DE69826496T DE69826496D1 DE 69826496 D1 DE69826496 D1 DE 69826496D1 DE 69826496 T DE69826496 T DE 69826496T DE 69826496 T DE69826496 T DE 69826496T DE 69826496 D1 DE69826496 D1 DE 69826496D1
Authority
DE
Germany
Prior art keywords
disclosed
recombinantes
iga
antibodies
epithelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69826496T
Other languages
English (en)
Other versions
DE69826496T2 (de
Inventor
Donald Capra
M Hexham
N Carayannopoulos
E Max
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
University of Texas System
Original Assignee
US Department of Health and Human Services
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, University of Texas System filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69826496D1 publication Critical patent/DE69826496D1/de
Publication of DE69826496T2 publication Critical patent/DE69826496T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69826496T 1997-01-07 1998-01-07 RECOMBINANTES IgA Expired - Fee Related DE69826496T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/779,597 US6063905A (en) 1997-01-07 1997-01-07 Recombinant human IGA-J. chain dimer
US779597 1997-01-07
PCT/US1998/000614 WO1998030577A1 (en) 1997-01-07 1998-01-07 RECOMBINANT HUMAN IgA-J. CHAIN DIMER

Publications (2)

Publication Number Publication Date
DE69826496D1 true DE69826496D1 (de) 2004-10-28
DE69826496T2 DE69826496T2 (de) 2005-12-01

Family

ID=25116928

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69826496T Expired - Fee Related DE69826496T2 (de) 1997-01-07 1998-01-07 RECOMBINANTES IgA

Country Status (7)

Country Link
US (2) US6063905A (de)
EP (1) EP1009756B1 (de)
AT (1) ATE277082T1 (de)
AU (1) AU728748B2 (de)
CA (1) CA2278344A1 (de)
DE (1) DE69826496T2 (de)
WO (1) WO1998030577A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045774A (en) * 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
AU740918B2 (en) 1997-01-10 2001-11-15 Plantibodies Corporation Novel epithelial tissue targeting agent
AU2001283304B2 (en) * 2000-08-11 2005-05-05 Favrille, Inc. Method and composition for altering a T cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US6932967B2 (en) * 2001-03-22 2005-08-23 Michael R. Simon Human medical treatment by aerosol inhalation of immunoglobulin A
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
US7291477B2 (en) 2001-07-03 2007-11-06 Xenotope Diagnostics, Inc. Method and device for trichomonas detection
US20060165675A1 (en) * 2002-08-02 2006-07-27 Richman-Eisenstat Janice Beth Modulation of mesenchymal cells via iga-receptors
US7566447B2 (en) 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
US20050014932A1 (en) * 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
NZ544923A (en) * 2003-06-27 2009-02-28 Biogen Idec Inc Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous anti-body solutions
AU2004276306A1 (en) * 2003-09-23 2005-04-07 Favrille, Inc. Altering a B cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent
WO2005060520A2 (en) * 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
EP1812550A2 (de) * 2004-10-20 2007-08-01 Iogenetics, Llc Biozide
MX2007004437A (es) * 2004-10-22 2007-06-20 Amgen Inc Metodos para el repliegue de anticuerpos recombinantes.
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US8017103B2 (en) * 2005-07-01 2011-09-13 Board Of Regents, The University Of Texas System Methods and compositions to diagnose trichomonas infection
US20070015224A1 (en) * 2005-07-01 2007-01-18 Board Of Regents, The University Of Texas System Methods and compositions to diagnose Trichomonas infection
US7439028B2 (en) * 2005-09-30 2008-10-21 Board Of Regents, The University Of Texas System Methods and compositions to correlate Trichomonas infection with prostate cancer
US7803567B2 (en) * 2005-12-09 2010-09-28 Board Of Regents, The University Of Texas System Methods and compositions for detecting trichomonas in a sample contacted with fixative
US8481023B2 (en) 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
JP5963341B2 (ja) * 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
EP2691530B1 (de) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv-glycoproteine und rekombinante vektoren
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
EP2895511A4 (de) * 2012-09-10 2016-04-13 Lfb Usa Inc Verwendung von antikörpern zur behandlung von hiv-infektionen und zur unterdrückung der übertragung von hiv
TW201506041A (zh) 2013-02-13 2015-02-16 Lab Francais Du Fractionnement 高度半乳糖基化的抗腫瘤壞死因子阿爾法抗體及其用途
CN105263319A (zh) 2013-02-13 2016-01-20 法国化学与生物科技实验室 具有经修饰的糖基化的蛋白及其生产方法
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10925962B2 (en) * 2014-07-18 2021-02-23 Nippi, Incorporated Polymeric IgA-type recombinant antibody and use thereof
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
AU2016238246B2 (en) 2015-03-25 2021-05-13 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
US10279031B2 (en) 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
WO2022073066A1 (en) * 2020-10-06 2022-04-14 Macfarlane Burnet Institute For Medical Research And Public Health Limited Methods and compositions based on longitudinal studies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response

Also Published As

Publication number Publication date
DE69826496T2 (de) 2005-12-01
ATE277082T1 (de) 2004-10-15
EP1009756A1 (de) 2000-06-21
US6063905A (en) 2000-05-16
AU5915498A (en) 1998-08-03
EP1009756A4 (de) 2001-11-21
AU728748B2 (en) 2001-01-18
US6673342B1 (en) 2004-01-06
CA2278344A1 (en) 1998-07-16
EP1009756B1 (de) 2004-09-22
WO1998030577A1 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
DE69826496D1 (de) RECOMBINANTES IgA
ATE328068T1 (de) Papillomavirus vakzine
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
WO2001034801A3 (en) Recombinant gelatin in vaccines
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
PL339735A1 (en) Pappiloma virus capsomer vaccine compositions and methods of applying them
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
RS51635B (sr) Antitela koja blokiraju cripto i njihova upotreba
WO1999033868A3 (en) Human papillomavirus vaccine
RS51157B (sr) Baff receptor (bcma), imunoregulatorni agens
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
DK0675733T3 (da) Peptid-carbohydrat-konjugater, der genererer T-celleimmunitet
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
DE69919984D1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
DE69735062D1 (de) Impfstoffherstellung des bacillus anthracis schutzantigens
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
AU4985596A (en) Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
GB9723945D0 (en) Tissue cement
FI946076A (fi) Modifioituja Kluyveromyces-hiivoja, valmistus ja käyttö
SI1173194T1 (en) Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation
AU2002229850A1 (en) Polypeptide inducing hiv-neutralising antibodies
EP1015560A4 (de) Veränderte, kleine rna-viren
AU2001270226A1 (en) Tolerance and chronic hepatitis c virus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee